Sorrento Therapeutics (NASDAQ:SRNE – Get Rating) and Allogene Therapeutics (NASDAQ:ALLO – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, profitability, analyst recommendations, institutional ownership, valuation and dividends. Institutional and Insider Ownership 27.0% of Sorrento Therapeutics shares […]
Wall Street brokerages expect Sorrento Therapeutics, Inc. (NASDAQ:SRNE – Get Rating) to report sales of $17.83 million for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for Sorrento Therapeutics’ earnings, with the lowest sales estimate coming in at $14.54 million and the highest estimate coming in at $21.12 million. Sorrento Therapeutics […]
Analysts expect that Sorrento Therapeutics, Inc. (NASDAQ:SRNE – Get Rating) will announce ($0.25) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have provided estimates for Sorrento Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.22) and the lowest estimate coming in at ($0.28). Sorrento Therapeutics posted earnings per […]
Sorrento Therapeutics (NASDAQ:SRNE – Get Rating) had its target price reduced by HC Wainwright from $26.00 to $20.00 in a report issued on Friday morning, The Fly reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. Other analysts also recently issued research reports about the company. Zacks Investment Research raised Sorrento […]
Inc.
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.
Sorrento s commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), an